XENE · XBRL financial data

Xenon Pharmaceuticals financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (XENE's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	51	75	106	168	210	301
General and administrative	13	22	33	47	69	80
Total operating expenses	63	97	139	214	279	381
Operating income (loss)	(31)	(79)	(129)	(214)	(279)	(373)
Interest income	2	0	9	28	42	27
Interest expense	0	—	—	—	—	—
Income tax expense (benefit)	(0)	(0)	0	(0)	(4)	1
Net income (loss)	(29)	(79)	(125)	(182)	(234)	(346)
Earnings per share, basic USD per share	(0.81)	(1.77)	(2.06)	(2.73)	(3.01)	(4.36)
Earnings per share, diluted USD per share	(0.81)	(1.77)	(2.06)	(2.73)	(3.01)	(4.36)
Weighted average shares, basic millions of shares	35	44	61	67	78	79
Weighted average shares, diluted millions of shares	35	44	61	67	78	79

Fiscal years (XENE's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	45	176	57	149	143	199
Marketable securities	132	376	535	489	484	350
Marketable securities, non-current	—	0	129	293	127	37
Accounts receivable	2	3	1	1	1	—
Prepaid and other current assets	3	4	7	6	7	10
Total current assets	182	559	600	645	635	561
Property and equipment, net	4	4	7	10	10	9
Right-of-use asset	3	8	10	9	8	7
Total assets	189	572	754	965	798	633
Accrued liabilities	—	—	—	—	—	36
Total current liabilities	15	14	23	27	36	42
Lease liability, non-current	3	8	10	10	8	6
Total liabilities	18	22	33	37	43	51
Accumulated deficit	(278)	(357)	(483)	(665)	(899)	(1,245)
Total stockholders' equity	171	550	721	928	755	582
Total liabilities and equity	189	572	754	965	798	633
Common shares outstanding (cover page) millions of shares	36	52	63	75	77	83

Fiscal years (XENE's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(29)	(79)	(125)	(182)	(234)	(346)
Stock-based compensation	6	10	20	32	51	54
Net cash from operating activities	(48)	(70)	(98)	(145)	(181)	(279)
Purchases of property and equipment	3	2	3	6	3	1
Net cash from investing activities	(17)	(247)	(296)	(117)	165	218
Proceeds from issuing common stock	102	—	—	—	—	—
Net cash from financing activities	86	448	278	354	12	117
Net change in cash	20	131	(118)	91	(6)	56

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Xenon Pharmaceuticals	120	not reported	(95)*	96.8M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Summit Therapeutics	151	not reported	not reported	799.8M	—	Q3 FY26 10-QSep 30, 2026
Twist Bioscience	117	not reported	1.1*	62.7M	—	Q3 FY26 10-QJun 30, 2026
Cytokinetics	203	48	not reported	139.3M	—	Q3 FY26 10-QSep 30, 2026
TG Therapeutics	483	240	39*	153.1M	—	Q2 FY26 10-QJun 30, 2026
Catalyst Pharmaceuticals	756	149	60	122.4M	—	Q1 FY26 10-QMar 31, 2026
Acadia Pharmaceuticals	385	308	101*	172.3M	—	Q2 FY26 10-QJun 30, 2026
Vericel	125	77	16*	51.2M	—	Q2 FY26 10-QJun 30, 2026
Recursion Pharmaceuticals	550	19	(77)*	622.8M	6.2 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.